Daniel O'Day's most recent trade in Gilead Sciences, Inc. was a trade of 10,000 Common Stock done at an average price of $136.8 . Disclosure was reported to the exchange on March 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 136.82 per share. | 27 Mar 2026 | 10,000 | 642,567 (0%) | 0% | 136.8 | 1,368,162 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 122,755 | 122,755 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 32,815 | 100,859 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 20,026 | 68,044 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 20,026 | 662,334 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.56 per share. | 10 Mar 2026 | 9,767 | 652,567 (0%) | 0% | 148.6 | 1,450,986 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2026 | 115,640 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 150.00 per share. | 05 Feb 2026 | 115,640 | 613,912 (0%) | 0% | 150 | 17,346,000 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 05 Feb 2026 | 115,640 | 729,552 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 131,675 | 688,373 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.28 per share. | 03 Feb 2026 | 74,461 | 613,912 (0%) | 0% | 143.3 | 10,668,772 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 139.54 per share. | 28 Jan 2026 | 5,032 | 561,666 (0%) | 0% | 139.5 | 702,186 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 140.24 per share. | 28 Jan 2026 | 4,968 | 556,698 (0%) | 0% | 140.2 | 696,725 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.01 per share. | 23 Jan 2026 | 115,640 | 682,338 (0%) | 0% | 66.0 | 7,633,396 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2026 | 115,640 | 115,640 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 23 Jan 2026 | 115,640 | 566,698 (0%) | 0% | 135 | 15,611,400 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 124.83 per share. | 29 Dec 2025 | 10,000 | 566,698 (0%) | 0% | 124.8 | 1,248,272 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 88,070 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 10,426 | 581,629 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.34 per share. | 10 Dec 2025 | 4,931 | 576,698 (0%) | 0% | 121.3 | 598,328 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 126.84 per share. | 28 Nov 2025 | 6,788 | 571,203 (0%) | 0% | 126.8 | 861,016 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 125.91 per share. | 28 Nov 2025 | 3,212 | 577,991 (0%) | 0% | 125.9 | 404,428 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 119.54 per share. | 28 Oct 2025 | 7,978 | 583,225 (0%) | 0% | 119.5 | 953,667 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 118.82 per share. | 28 Oct 2025 | 2,022 | 581,203 (0%) | 0% | 118.8 | 240,259 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.47 per share. | 29 Sep 2025 | 8,039 | 593,164 (0%) | 0% | 111.5 | 896,110 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 112.42 per share. | 29 Sep 2025 | 1,961 | 591,203 (0%) | 0% | 112.4 | 220,454 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 606,152 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 10,427 | 98,496 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.25 per share. | 10 Sep 2025 | 4,949 | 601,203 (0%) | 0% | 115.2 | 570,372 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.63 per share. | 28 Aug 2025 | 10,000 | 595,725 (0%) | 0% | 113.6 | 1,136,300 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 114.09 per share. | 28 Jul 2025 | 8,345 | 605,725 (0%) | 0% | 114.1 | 952,077 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.17 per share. | 28 Jul 2025 | 1,655 | 614,070 (0%) | 0% | 113.2 | 187,293 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.40 per share. | 30 Jun 2025 | 9,400 | 616,325 (0%) | 0% | 110.4 | 1,037,796 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 111.15 per share. | 30 Jun 2025 | 600 | 615,725 (0%) | 0% | 111.1 | 66,688 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 108,923 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 10,425 | 630,693 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 4,968 | 625,725 (0%) | 0% | 110.1 | 546,927 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.11 per share. | 30 May 2025 | 6,416 | 623,852 (0%) | 0% | 110.1 | 706,497 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.96 per share. | 30 May 2025 | 3,584 | 620,268 (0%) | 0% | 111.0 | 397,696 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 169,690 | 169,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,395 | 119,348 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 80,953 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 641,900 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 11,632 | 630,268 (0%) | 0% | 117.2 | 1,363,387 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 164,473 | 726,032 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 108,156 | 617,876 (0%) | 0% | 98.0 | 10,598,206 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,031 | 561,559 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 506,290 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 104,977 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 4,762 | 501,528 (0%) | 0% | 92.3 | 439,723 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 500,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 115,272 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 4,749 | 495,995 (0%) | 0% | 81.4 | 386,759 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 125,567 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 495,142 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 4,693 | 490,449 (0%) | 0% | 65.2 | 306,218 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 279,130 | 279,130 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 54,910 | 135,862 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,140 | 80,952 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,140 | 498,629 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 13,782 | 484,847 (0%) | 0% | 75.1 | 1,035,304 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 10,800 | 479,489 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 10,800 | 100,092 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 179,877 | 548,024 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.26 per share. | 31 Jan 2024 | 79,335 | 468,689 (0%) | 0% | 78.3 | 6,208,757 | Common Stock |
| Gilead Sciences | O'Day Daniel | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 50,870 | 368,147 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | O'Day Daniel | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 7,347 | 391,032 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 7,347 | 110,892 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.02 per share. | 10 Dec 2023 | 3,341 | 387,691 (0%) | 0% | 79.0 | 264,006 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 7,346 | 125,587 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 7,346 | 269,534 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.12 per share. | 10 Jun 2023 | 3,409 | 266,125 (0%) | 0% | 78.1 | 266,311 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 215,095 | 215,095 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 47,170 | 132,933 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 19,488 | 96,563 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 19,488 | 378,983 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.50 per share. | 10 Mar 2023 | 14,017 | 375,766 (0%) | 0% | 79.5 | 1,114,352 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 10,800 | 389,783 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 10,800 | 85,763 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,362 | 116,051 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,362 | 364,337 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.59 per share. | 01 Mar 2023 | 4,842 | 359,495 (0%) | 0% | 79.6 | 385,375 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 136,647 | 412,053 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 78,370 | 275,406 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.02 per share. | 24 Jan 2023 | 59,078 | 352,975 (0%) | 0% | 84.0 | 4,963,734 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 3,300 | 127,413 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 3,300 | 256,178 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.97 per share. | 10 Dec 2022 | 1,542 | 254,636 (0%) | 0% | 88.0 | 135,650 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 3,301 | 254,406 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 3,301 | 130,713 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.28 per share. | 10 Sep 2022 | 1,528 | 252,878 (0%) | 0% | 65.3 | 99,748 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 3,300 | 134,014 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 3,300 | 252,644 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.74 per share. | 10 Jun 2022 | 1,539 | 251,105 (0%) | 0% | 60.7 | 93,479 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 399,235 | 399,235 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 64,745 | 137,314 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 13,203 | 72,569 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 13,203 | 260,396 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.92 per share. | 10 Mar 2022 | 11,052 | 249,344 (0%) | 0% | 57.9 | 640,132 | Common Stock |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 10,800 | 247,193 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 10,800 | 85,772 | - | - | Restricted Stock Unit |